WO2001064204A3 - Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents - Google Patents

Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents Download PDF

Info

Publication number
WO2001064204A3
WO2001064204A3 PCT/IT2001/000082 IT0100082W WO0164204A3 WO 2001064204 A3 WO2001064204 A3 WO 2001064204A3 IT 0100082 W IT0100082 W IT 0100082W WO 0164204 A3 WO0164204 A3 WO 0164204A3
Authority
WO
WIPO (PCT)
Prior art keywords
prevention
treatment
composition
immunosuppressive agents
cytotoxic effects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IT2001/000082
Other languages
French (fr)
Other versions
WO2001064204A2 (en
Inventor
Claudio Cavazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau HealthScience SpA
Original Assignee
Sigma Tau HealthScience SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SK1189-2002A priority Critical patent/SK11892002A3/en
Priority to AU2001241031A priority patent/AU2001241031B8/en
Priority to PL358267A priority patent/PL202682B1/en
Priority to MXPA02008531A priority patent/MXPA02008531A/en
Priority to HU0300083A priority patent/HUP0300083A3/en
Priority to AU4103101A priority patent/AU4103101A/en
Priority to US10/220,185 priority patent/US7897641B2/en
Priority to DE60122120T priority patent/DE60122120T2/en
Application filed by Sigma Tau HealthScience SpA filed Critical Sigma Tau HealthScience SpA
Priority to EP01912114A priority patent/EP1267863B1/en
Priority to CA002400728A priority patent/CA2400728C/en
Publication of WO2001064204A2 publication Critical patent/WO2001064204A2/en
Publication of WO2001064204A3 publication Critical patent/WO2001064204A3/en
Anticipated expiration legal-status Critical
Priority to CY20061101374T priority patent/CY1106169T1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A composition is disclosed which is suitable for the prevention and/or treatment of cell and tissue abnormalities of exogenous, toxic or metabolic origin and suitable for reducing the toxic effects of cyclosporin-A and other immunosuppressive agents, which may take the form of a food supplement or of an actual medicine, containing as its active ingredients in combination or separately packaged: (a) propionyl L-carnitine or one of its pharmacologically acceptable salts, and (b) an amino acid selected from the group consisting of glycine, serine, alanine and arginine, or mixtures thereof.
PCT/IT2001/000082 2000-03-02 2001-02-20 Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents Ceased WO2001064204A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US10/220,185 US7897641B2 (en) 2000-03-02 2001-02-20 Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents
PL358267A PL202682B1 (en) 2000-03-02 2001-02-20 Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents
MXPA02008531A MXPA02008531A (en) 2000-03-02 2001-02-20 Composition for the prevention and or treatment of the cytotoxic effects induced by the use of immunosuppressive agents.
HU0300083A HUP0300083A3 (en) 2000-03-02 2001-02-20 Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents
AU4103101A AU4103101A (en) 2000-03-02 2001-02-20 Composition for the prevention and/or treatment of the cytotoxic effects inducedby the use of immunosuppressive agents
DE60122120T DE60122120T2 (en) 2000-03-02 2001-02-20 COMPOSITION COMPRISING PROPIONYL L-CARNITINE AND GLYCINE FOR THE PREVENTION AND / OR TREATMENT OF CYTOTOXIC EFFECTS DUE TO THE USE OF IMMUNOSUPPRESSIVES
EP01912114A EP1267863B1 (en) 2000-03-02 2001-02-20 Composition consisting of propionyl l-carnitine and glycine for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents
SK1189-2002A SK11892002A3 (en) 2000-03-02 2001-02-20 Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents
AU2001241031A AU2001241031B8 (en) 2000-03-02 2001-02-20 Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents
CA002400728A CA2400728C (en) 2000-03-02 2001-02-20 Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents
CY20061101374T CY1106169T1 (en) 2000-03-02 2006-09-25 COMPOSITION OF PROPIONYL L-CARNITINE AND GLYCINE FOR THE PREVENTION AND/OR TREATMENT OF CYTOTOXIC EFFECTS INDUCED BY THE USE OF IMMUNOSUPPRESSANT AGENTS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2000RM000107A IT1316998B1 (en) 2000-03-02 2000-03-02 COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF TOXIC EFFECTS INDUCED BY THE USE OF IMMUNOSOPPRESSING AGENTS.
ITRM2000A000107 2000-03-02

Publications (2)

Publication Number Publication Date
WO2001064204A2 WO2001064204A2 (en) 2001-09-07
WO2001064204A3 true WO2001064204A3 (en) 2002-03-28

Family

ID=11454493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2001/000082 Ceased WO2001064204A2 (en) 2000-03-02 2001-02-20 Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents

Country Status (19)

Country Link
US (1) US7897641B2 (en)
EP (1) EP1267863B1 (en)
AR (1) AR027963A1 (en)
AT (1) ATE335476T1 (en)
AU (2) AU2001241031B8 (en)
CA (1) CA2400728C (en)
CY (1) CY1106169T1 (en)
CZ (1) CZ20022759A3 (en)
DE (1) DE60122120T2 (en)
DK (1) DK1267863T3 (en)
ES (1) ES2269356T3 (en)
HU (1) HUP0300083A3 (en)
IT (1) IT1316998B1 (en)
MX (1) MXPA02008531A (en)
PL (1) PL202682B1 (en)
PT (1) PT1267863E (en)
SK (1) SK11892002A3 (en)
TN (1) TNSN01032A1 (en)
WO (1) WO2001064204A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6775419B2 (en) * 2014-04-22 2020-10-28 味の素株式会社 Composition for prevention or improvement of peripheral neuropathy
CN115469026B (en) * 2022-07-14 2023-10-20 中日友好医院(中日友好临床医学研究所) Detection reagents and kits for detecting markers related to cyclosporine A nephrotoxicity and their uses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955424A (en) * 1995-01-20 1999-09-21 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of L-carnitine and its alkanoyl derivatives for reducing the toxic effects of cyclosporin-A and other immunosuppressant drugs
WO2000028986A1 (en) * 1998-11-13 2000-05-25 Sigma-Tau Healthscience S.P.A. Antioxidant composition comprising propionyl l-carnitine and a flavonoid against thrombosis and atherosclerosis
WO2000062773A1 (en) * 1999-04-16 2000-10-26 Sigma-Tau Healthscience S.P.A. Composition comprising a carnitine and glutathione, useful to increase the absorption of glutathione and synergize its effects

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1120033B (en) * 1979-10-05 1986-03-19 Sigma Tau Ind Farmaceuti INCLUDING PHARMACEUTICAL COMPOSITION-CARNITINE SUITABLE FOR PARENTERAL FEEDING
US5290538A (en) * 1988-12-22 1994-03-01 Skrezek Christian Nephro protective infusion solutions
JPH0662547B2 (en) * 1989-01-10 1994-08-17 田辺製薬株式会社 Glycine derivative
IT1248323B (en) * 1991-05-16 1995-01-05 Sigma Tau Ind Farmaceuti STARCHES WITH NATURAL AMINO ACIDS OF ALCANOIL L-CARNITINE AS INHIBITORS OF THE NEURONAL DEGENERATION AND ACTIVATORS OF THE LEARNING AND STORING PROCESSES AND FOR THE TREATMENT OF THE COMA AND PHARMACEUTICAL COMPOSITIONS INCLUDING SUCH COMPOUNDS
IT1245869B (en) 1991-06-05 1994-10-25 Sigma Tau Ind Farmaceuti USE OF PROPIONIL L-CARNITINA FOR THE RECOVERY OF THE MUSCLE TONE IN IMMOBILIZED SUBJECTS
US5763408A (en) * 1992-06-03 1998-06-09 Fuji Photo Film Co., Ltd. Amino acid derivatives and application thereof
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
ATE187329T1 (en) * 1996-03-04 1999-12-15 Sigma Tau Ind Farmaceuti CARNITINE DERIVATIVE AS A MEDICINAL PRODUCT FOR THE TREATMENT OF ARTERIOSCLEROSIS OBLITERANS
US6348495B1 (en) * 1996-06-06 2002-02-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Method for treating celiac disease
IT1291113B1 (en) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti NUTRITIONAL THERAPEUTIC COMPOSITION FOR SUBJECTS WITH DIABETES MELLITUS
IT1291127B1 (en) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti FOOD SUPPLEMENT FOR SUBJECTS DEDICATED TO INTENSE AND PROLONGED PHYSICAL ACTIVITY
US5922766A (en) * 1997-07-02 1999-07-13 Acosta; Phyllis J. B. Palatable elemental medical food
IT1306173B1 (en) * 1999-07-23 2001-05-30 Sigma Tau Healthscience Spa COMPOSITION FOR THE PREVENTION OF MUSCLE FATIGUE AND TO IMPROVE THE MUSCLE ENERGY PERFORMANCE.
IT1306722B1 (en) * 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF CIRCULATORY DYSFUNCTIONS, INCLUDING L-CARNITINE DERIVATIVES AND EXTRACTS OF
IT1307278B1 (en) * 1999-11-18 2001-10-30 Sigma Tau Healthscience Spa COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF DISORDERS DUE TO AN ALTERED LIPID METABOLISM, INCLUDING PROPIONIL
IT1317062B1 (en) * 2000-07-14 2003-05-26 Sigma Tau Healthscience Spa FOOD SUPPLEMENT USEFUL TO PREVENT EBILARY HEPATIC DYSFUNCTIONS INCLUDING AN ALCANOIL L-CARNITINE.
ITRM20010155A1 (en) * 2001-03-23 2002-09-23 Biosalts Srl CREATINE SALT WITH INCREASED NUTRITIONAL AND THERAPEUTIC VALUE AND COMPOSITIONS THAT CONTAIN IT.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955424A (en) * 1995-01-20 1999-09-21 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of L-carnitine and its alkanoyl derivatives for reducing the toxic effects of cyclosporin-A and other immunosuppressant drugs
WO2000028986A1 (en) * 1998-11-13 2000-05-25 Sigma-Tau Healthscience S.P.A. Antioxidant composition comprising propionyl l-carnitine and a flavonoid against thrombosis and atherosclerosis
WO2000062773A1 (en) * 1999-04-16 2000-10-26 Sigma-Tau Healthscience S.P.A. Composition comprising a carnitine and glutathione, useful to increase the absorption of glutathione and synergize its effects

Also Published As

Publication number Publication date
HUP0300083A3 (en) 2004-07-28
ATE335476T1 (en) 2006-09-15
AU2001241031B2 (en) 2005-10-27
PL202682B1 (en) 2009-07-31
AU2001241031B8 (en) 2005-12-01
CZ20022759A3 (en) 2003-02-12
DE60122120T2 (en) 2007-02-08
ITRM20000107A1 (en) 2001-09-02
EP1267863B1 (en) 2006-08-09
AR027963A1 (en) 2003-04-16
EP1267863A2 (en) 2003-01-02
PL358267A1 (en) 2004-08-09
DK1267863T3 (en) 2006-12-04
CA2400728C (en) 2009-04-28
PT1267863E (en) 2006-10-31
HUP0300083A2 (en) 2003-06-28
AU4103101A (en) 2001-09-12
IT1316998B1 (en) 2003-05-26
DE60122120D1 (en) 2006-09-21
SK11892002A3 (en) 2003-02-04
MXPA02008531A (en) 2003-02-12
WO2001064204A2 (en) 2001-09-07
TNSN01032A1 (en) 2005-11-10
US7897641B2 (en) 2011-03-01
ES2269356T3 (en) 2007-04-01
CY1106169T1 (en) 2011-06-08
US20030144354A1 (en) 2003-07-31
ITRM20000107A0 (en) 2000-03-02
CA2400728A1 (en) 2001-09-07

Similar Documents

Publication Publication Date Title
CA2411754A1 (en) 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoic acid and compositions for delivering active agents
CA2320039A1 (en) Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
WO2003079972A3 (en) Active agent delivery systems and methods for protecting and administering active agents
CA2334919A1 (en) Composition comprising a carnitine and glutathione, useful to increase the absorption of glutathione and synergize its effects
WO2002047715A3 (en) Compositions of peptide crystals
CA2322188A1 (en) The use of fumaric acid derivatives in transplant medicine
CA2258920A1 (en) Autocross-linked hyaluronic acid and related pharmaceutical compositions for the treatment of arthropathies
EP1246792A4 (en) COMPOUNDS AND COMPOSITIONS FOR ADMINISTERING ACTIVE INGREDIENTS
CA2408142A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IL150895A0 (en) Oral, nasal and pulmonary formulations of copolymer-1
IL109186A0 (en) Stable, ingestable and absorbable nadh and nadph therapeutic compositions
CA2370201A1 (en) Skin care compositions containing a combination of skin care actives
CA2333601A1 (en) Surfactant for use in external preparations for skin and external preparation for skin containing the same
CA2377174A1 (en) Oral administration forms for administering a fixed tramadol and diclofenac combination
FR2846883B1 (en) COSMETIC COMPOSITION COMPRISING, AS ACTIVE INGREDIENT, AT LEAST ONE PEPTIDE AND USE OF THIS PEPTIDE
TW200833321A (en) Pharmaceutical composition for treating hypertension, diabetes mellitus and cardiovascular diseases
WO2003013487A3 (en) Amino-acid-based compositions, suitable in therapy for the healing and/or mending of wounds and lesions, in particular for application in the ophthalmic field
GB9718568D0 (en) Compositions
MXPA04003540A (en) Use of a copolymer to produce a galenic form containing a peptide or a protein as active agent.
CA2400728A1 (en) Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents
CA2331961A1 (en) Sweetener composition
WO2002011709A3 (en) Pharmaceutical, effervescent formulation containing ramipril
CA2331768A1 (en) Sweetener composition
CA2301889A1 (en) Water-soluble dry compositions
CA2263184A1 (en) Methods and compositions for increasing the anaerobic working capacity in tissues

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001912114

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV2002-2759

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 11892002

Country of ref document: SK

Ref document number: 2001241031

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2400728

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/008531

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 10220185

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001912114

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-2759

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: PV2002-2759

Country of ref document: CZ

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2001241031

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2001912114

Country of ref document: EP